Obesity White Papers & Case Studies

  1. Preparing The Next Generation Of Clinical Research Professionals 9/4/2025

    Explore the live EDC platform that enabled Durham Tech to create a model for future-forward, hands-on education in clinical research.

  2. Advancing Alzheimer's Disease Therapies 9/3/2025

    By uniting scientific innovation with patient-focused execution, the next generation of alzheimer’s disease (AD) therapies has the potential to deliver a transformative impact on global health.

  3. De-Risking Early-Stage Biotech: Turning Vision Into Venture Capital 9/3/2025

    For early-stage biotech companies, transforming a scientific breakthrough into an investable asset requires more than compelling data—it requires a clear product vision.

  4. From Innovation To Patient Impact 9/3/2025

    Biotech innovation is redefining the future of healthcare — but translating breakthroughs into patient impact requires the right partner.

  5. Writing An IND Module 3 For Cell And Gene Therapy Products 9/1/2025

    This whitepaper outlines the critical considerations for CGT Investigational New Drug (IND) Module 3, as well as how to avoid clinical holds and ensure regulatory readiness.

  6. Enhancing Clinical Trial Flexibility 9/1/2025

    Once seen primarily as staffing extensions, FSPs have evolved into strategic partners that deliver flexibility, scalability, and tailored expertise.

  7. Generate High- Quality Evidence For Pediatric Trials 9/1/2025

    Generate the high-quality data required to advance safe and effective therapies for children with solutions that address the unique challenges of pediatric trials.

  8. Navigating Project Optimus And The Rapidly Changing Oncology Development Landscape 9/1/2025

    Project Optimus and adaptive trial designs are reshaping oncology development, improving patient outcomes, and streamlining approval pathways.

  9. Accelerating Approval Pathway For Phase III Ovarian Cancer Trial 8/29/2025

    A late-stage biotech developing a first-in-class therapy for a rare, chemo-resistant form of ovarian cancer sought help for accelerated FDA approval.

  10. The Untapped Power Of Real-World Data And AI In Pharma Commercialization 8/27/2025

    Harnessing RWD in commercialization bridges the gap between approval and patient access, equipping companies with actionable intelligence to deliver life-changing therapies to more patients.